A long-term study shows benefits of H. pylori eradication and supplementation with vitamins and garlic.
Rates of bleeding, progressive CVT, and recurrent venous thromboembolism were similar with dabigatran or warfarin.
Among cancer patients 65 years of age and older, outcomes were significantly worse among those with HIV infection.
In a real-world comparison, the benefit-to-risk ratio favored apixaban with similar efficacy and lower rates of bleeding.
Update recommends that providers use a risk assessment tool for all women with personal or family history of breast and ovarian cancer.
The USPSTF recommends that providers discuss use of tamoxifen, raloxifene, or aromatase inhibitors with women at excess risk for breast cancer and low risk for adverse effects.
Patients undergoing the procedure with immediate breast reconstruction had a low incidence of cancer recurrence at the nipple-areola complex.
A small proportion of metachronous colorectal cancers could be due to seeding from colonoscopic manipulation of the primary tumor.
Programmatic, multiple-round FIT detected more neoplasia than one-time sigmoidoscopy or colonoscopy in the intention-to-screen analysis, but there is more to the story.
A quarter of patients responded to the oral agent selinexor, an inhibitor of the nuclear export protein exportin 1.
Prof. Dr. med. Christoph Rochlitz
E-Mail: E-Mail anzeigen
In der vorliegenden Ausgabe von NEJM Journal Watch möchte ich Ihnen gerne wieder einige rezent publizierte Studien aus dem Bereich Onkologie/Hämatologie näherbringen.
Metastasis-free survival was significantly longer with apalutamide than with placebo.
Contrary to prior findings, adding olaparib to paclitaxel failed to improve survival in patients with disease progression following chemotherapy.
Assessment of tumor mutation burden using targeted next-generation sequencing may be predictive of benefit from PD-1 and PD-L1 inhibitors.
Outcomes were not superior with 5 versus 2.5 years of extended letrozole therapy.
Overall survival was significantly shorter among MGUS patients than among a matched control population in a long-term follow-up study.
Survival is similar between BRCA mutation carriers versus those with sporadic disease.
Adding tumor-treating electrical-field therapy to maintenance temozolomide chemotherapy significantly improved survival in patients with newly diagnosed glioblastoma.
Overall survival was not improved with the PD-L1 inhibitor atezolizumab versus chemotherapy in patients with highest PD-L1 expression.
First-line therapy demonstrated antitumor activity in a phase II study.
Disease-free survival is significantly improved in patients who restart therapy versus those who do not restart after discontinuation.